Wednesday, July 8, 2026

Drug profile · INN

potassium phosphate, dibasic

potassium phosphate, dibasic (POTASSIUM PHOSPHATES) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — potassium phosphate, dibasic
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
3
Data quality
0.89

Quick answer

potassium phosphate, dibasic (POTASSIUM PHOSPHATES) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN potassium phosphate, dibasic
Brand POTASSIUM PHOSPHATES
Route INTRAVENOUS
Formulation SOLUTION

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. 0.9% sodium chloride Phase 2 · First People's Hospital · Kidney Disease, Chronic
  2. Basic treatment Unknown · First People's Hospital · Major Depressive Disorder
  3. Basic treatment Unknown · LianBio · Major Depressive Disorder

Frequently asked questions

What is potassium phosphate, dibasic?

potassium phosphate, dibasic (POTASSIUM PHOSPHATES) is an FDA-listed pharmaceutical active ingredient. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for potassium phosphate, dibasic?

POTASSIUM PHOSPHATES is a marketed brand name for potassium phosphate, dibasic. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of potassium phosphate, dibasic?

potassium phosphate, dibasic has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.